How We Work

Grant

Back

Print

Novavax, Inc.


September 2015
to advance to WHO Pre-Qualification the development of a respiratory syncytial virus (RSV) vaccine for maternal immunization to reduce the burden of RSV disease in infants less than six months of age in developing countries
$89,083,312
76
Pneumonia
Global Health
Gaithersburg, Maryland

Visit Our Blog